

Gilead-sponsored symposium at the 11th Trends in Medical Mycology Congress

Megaron Athens International Conference Centre, Athens, Greece

Saturday 21 October 2023, 18:00-19:30 EEST

Debate: This house believes IFI guidelines are of no clinical value

Symposium objectives:

- To hold a medical educational session, in the form of a debate, discussing the relevance of invasive fungal infection (IFI) management guidelines, and how these impact clinical practice
- The debate will cover both strengths and limitations of guidelines for a fruitful educational session with an aim to support informed treatment decisions for healthcare professionals involved in the management of IFI

Time	Session	Speaker(s)
18:00–18:10	Welcome, introduction to the debate and review of the agenda	Johan Maertens (Belgium)
18:10–18:15	Audience voting	All
18:15–18:30	Proposer to the motion "This house believes IFI guidelines are of no clinical value"	Ali Omrani (Qatar)
18:30–18:45	Opposer to the motion "This house believes IFI guidelines are of no clinical value"	Dionysios Neofytos (Switzerland)
18:45–18:50	Seconder proposer to the motion	Neil Clancy (US)
18:50–18:55	Seconder opposer to the motion	Samir Agrawal (UK)
18:55–19:05	Q&A	All
19:05–19:10	Proposer summary	Neil Clancy
19:10–19:15	Opposer summary	Samir Agrawal
19:15–19:20	Audience voting	All
19:20–19:30	Q&A, summary and close	Johan Maertens

HCP, healthcare professional; IFI, invasive fungal disease.

Biographies

Dr Ali Omrani MBBCh, MSc, FRCP, FRCPath

Dr Omrani is a Senior Consultant in Infectious Diseases at Hamad Medical Corporation, and a Clinical Professor of Infectious Diseases at the College of Medicine, Qatar University. His clinical and research interests focus on the management of infections caused by multi-resistant pathogens, and infections in immune compromised hosts. He is a frequent speaker at national and international medical events, and is lead author on numerous of original research articles, reviews and editorials.

Samir G. Agrawal - Biography 2023

Senior Lecturer in Haematology, Blizard Institute, Queen Mary University of London, and Consultant Haemato-Oncologist at St Bartholomew's Hospital, The Barts Health NHS Trust, London, UK.

Dr Agrawal has designed, funded, and implemented studies on myelodysplastic syndromes, invasive aspergillosis, and chronic lymphocytic leukemia. He is a NICE reviewer and the Haemato-Oncology representative on the UK IVIg initiative.

His current activities in the field of infection and specifically invasive fungal disease are:

- laboratory and clinical studies to improve the diagnosis of IFD in high-risk haematology patients looking at early diagnosis using novel biomarker and imaging technologies
- developing clinical guidelines and integrated care pathways for managing IFD in the high-risk haemato-oncology setting
- online tools to aid antimicrobial stewardship
- promoting best practice and highlighting new developments through educational meetings, eg, the Fungal Update meeting, which has become the largest such meeting in the UK dedicated to human fungal pathology (www.fungalupdate.org)
- Member of the fungal guideline group of ECIL and an author of the ECIL-6 update.
- Member of the fungal subgroup of government committee on antimicrobial resistance, ESPAUR
- management of febrile neutropenia